$1045 | Single User
$2575 | Global License

Payer Insights: RA [2016]: Bulletin #2 [Report Updated: 01-06-2017]

Published by FirstWord Pharma: 01 Jun 2017 | 107167 | In Stock

Introduction

This edition presents payer views on recent developments in the rheumatoid arthritis (RA) market. Topics include; recent positive opinion from the European Medicines Agency (EMA) for Regeneron/Sanofi’s Kevzara (sarilumab); recent approvals of biosimilar Enbrel and biosimilar Humira in the EU; and Eli Lilly/Incyte’s Olumiant (baricitinib) gaining marketing authorisation in the EU.

Business Questions:

How do payers intend to cover sarilumab? Will there be any restrictions?

Is sarilumab likely to be utilised as a first or second-line therapy?

What factors will determine the incorporation of sarilumab in formularies? What role will drug pricing and treatment guidelines play?

Will biosimilars of Enbrel and Humira capture market share from branded anti-TNFs?

Will the availability of biosimilar anti-TNFs improve patient access to RA treatment?

What role will payers play in switching patients to biosimilar anti-TNFs?

What patient subset will be targeted for switching to biosimilar anti-TNFs?

On what factors will the uptake of biosimilars be dependent on?

Will payers prefer biosimilars of Enbrel over biosimilars of Humira?

How are biosimilars of Remicade viewed by payers?

Are payers surprised that baricitinib was declined approval in the US, but not in the EU?

How important will discounts on baricitinib be for making reimbursement decisions?

Will the RA treatment paradigm shift towards oral and/or biosimilar agents?

Table of Contents
for Payer Insights: RA [2016]: Bulletin #2 [Report Updated: 01-06-2017]

Additional Details

Publisher

FirstWord Pharma

Publisher Information

Reference

107167 |

Report Format

PDF

FirstWord Pharma Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Biosimilars: US Payer Perspectives
IntroductionBiosimilars: US Payer Perspectives pulls back the curtain on the US biologics market and...
01 Apr 2015 by FirstWord Pharma USD $2,195 More Info
Harnessing the Power of Patient Support Programmes: pharma, patient and payer perspectives
IntroductionIt all started years ago, with a few patients asking questions on the internet. These da...
01 Apr 2015 by FirstWord Pharma USD $695 More Info
Payer Perspectives on Risk Sharing Deals
IntroductionRisk sharing agreements have been a strategic tool employed for more than a decade. Yet,...
01 Mar 2015 by FirstWord Pharma USD $695 More Info
Physician Views: Do cardiologists agree with payer rhetoric on PCSK9 inhibitors?
Scope Last week, CVS Health became the second pharmacy benefit manager (PBM) to publicly highlight t...
25 Feb 2015 by FirstWord Pharma USD $695 More Info
Biosimilars: European Payer Perspectives
IntroductionCost is king when it comes to European biosimilars. One issue unites European healthca...
06 Jan 2015 by FirstWord Pharma USD $2,195 More Info
Orphan Drug Market Access: Payer Insights on the Present and Future
IntroductionOrphan Drug Market Access: Payer Insights on the Present and Future is a report that exa...
14 Oct 2014 by FirstWord Pharma USD $695 More Info
Patient Assistance Programs: Payer and Pharma Perspectives
IntroductionPatient assistance programs (PAPs) are evolving in response to increasingly restrictive ...
02 Oct 2014 by FirstWord Pharma USD $695 More Info
Payer Insights: Hepatitis C
IntroductionThe race is on for the company that can competitively price treatment regimens, share da...
26 Sep 2014 by FirstWord Pharma USD $7,900 More Info
Oncology Market Access Europe – Payer and Industry Perspectives
IntroductionOncology Market Access Europe – Payer and Industry Perspectives answers your questions:W...
03 Jul 2014 by FirstWord Pharma USD $995 More Info
Pharma and the Changing US Payer Environment: Meeting the demands of Accountable Care Organizations (ACOs)
IntroductionThere’s a revolution happening...and it’s going to change the way pharma thinks. As the ...
01 Nov 2013 by FirstWord Pharma USD $695 More Info

This report is published by FirstWord Pharma

Download Free Report Summary PDF

Payer Insights: RA [2016]: Bulletin #2 [Report Updated: 01-06-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data